Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more
Market Cap & Net Worth: Celyad Oncology SA (CLYYF)
Celyad Oncology SA (PINK:CLYYF) has a market capitalization of $29.10 Million ($29.10 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #30188 globally and #9958 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celyad Oncology SA's stock price $0.65 by its total outstanding shares 44761905 (44.76 Million).
Celyad Oncology SA Market Cap History: 2016 to 2025
Celyad Oncology SA's market capitalization history from 2016 to 2025. Data shows change from $839.29 Million to $29.10 Million (-35.39% CAGR).
Celyad Oncology SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celyad Oncology SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
58.96x
Celyad Oncology SA's market cap is 58.96 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $839.29 Million | $10.01 Million | -$23.61 Million | 83.83x | N/A |
| 2017 | $1.73 Billion | $3.54 Million | -$56.40 Million | 489.98x | N/A |
| 2018 | $1.22 Billion | $3.12 Million | -$37.43 Million | 392.30x | N/A |
| 2019 | $503.57 Million | $6.00K | -$28.63 Million | 83928.57x | N/A |
| 2020 | $409.57 Million | $5.00K | -$17.20 Million | 81914.29x | N/A |
| 2023 | $19.33 Million | $102.00K | -$8.45 Million | 189.49x | N/A |
| 2024 | $10.97 Million | $186.00K | -$5.82 Million | 58.96x | N/A |
Competitor Companies of CLYYF by Market Capitalization
Companies near Celyad Oncology SA in the global market cap rankings as of March 19, 2026.
Key companies related to Celyad Oncology SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Celyad Oncology SA Historical Marketcap From 2016 to 2025
Between 2016 and today, Celyad Oncology SA's market cap moved from $839.29 Million to $ 29.10 Million, with a yearly change of -35.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $29.10 Million | +165.31% |
| 2024 | $10.97 Million | -43.26% |
| 2023 | $19.33 Million | -90.71% |
| 2022 | $208.14 Million | 0.00% |
| 2021 | $208.14 Million | -49.18% |
| 2020 | $409.57 Million | -18.67% |
| 2019 | $503.57 Million | -58.79% |
| 2018 | $1.22 Billion | -29.55% |
| 2017 | $1.73 Billion | +106.67% |
| 2016 | $839.29 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Celyad Oncology SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.10 Million USD |
| MoneyControl | $29.10 Million USD |
| MarketWatch | $29.10 Million USD |
| marketcap.company | $29.10 Million USD |
| Reuters | $29.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.